Runpeng Han

Mr. Runpeng Han

Medical Research Institute, Wuhan University, Wuhan, Hubei, China
orcid
Master in Biomedical Science

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
Runpeng HanRunpeng Han
Runpeng Han
Lishan SuLishan Su
Lishan Su
LCLiang Cheng
Liang Cheng
The development of effective vaccines against infectious diseases remains a critical challenge in global health. Animal models play a crucial role in vaccine development by providing valuable insights into the efficacy, safety, and mechanisms of immune response induction, which guide the design and formulation of vaccines. However, traditional animal models often inadequately recapitulate human immune responses. Humanized mice (hu-mice) models with a functional human immune system have emerged as invaluable tools in bridging the translational gap between preclinical research and clinical trials for human vaccine development. This review summarizes commonly used hu-mice models and advances in optimizing them to improve human immune responses. We review the application of humanized mice for human vaccine development with a focus on HIV-1 vaccines. We also discuss the remaining challenges and improvements needed for the currently available hu-mice models to better facilitate the development and testing of human vaccines for infectious diseases.

2 April 2026 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
LCLiang Cheng
Liang Cheng
GLGuangming Li
Guangming Li
FLFei Luo
Fei Luo
WBWenwen Bi
Wenwen Bi
MLMengmeng Lu
Mengmeng Lu
Lishan SuLishan Su
Lishan Su

20 April 2024 in Infectious Diseases & Immunity
Verified
Journal Article
Open access
Runpeng HanRunpeng Han
Runpeng Han
FLFei Luo
Fei Luo
HYHaisheng Yu
Haisheng Yu
YYYajun Yan
Yajun Yan
YGYan Gong
Yan Gong
LCLiang Cheng
Liang Cheng
Background: Human immunodeficiency virus type 1 (HIV-1) remains a persistent global health challenge. Therefore, a continuous exploration of novel therapeutic strategies is essential. A comprehensive understanding of how HIV-1 utilizes the cellular metabolism machinery for replication can provide insights into new therapeutic approaches. Methods: In this study, we performed a flux balance analysis using a genome-scale metabolic model (GEM) integrated with an HIV-1 viral biomass objective function to identify potential targets for anti–HIV-1 interventions. We generated a GEM by integrating an HIV-1 production reaction into CD4+ T cells and optimized for both host and virus optimal states as objective functions to depict metabolic profiles of cells in the status for optimal host biomass maintenance or for optimal HIV-1 virion production. Differential analysis was used to predict biochemical reactions altered optimal for HIV-1 production. In addition, we conducted in silico simulations involving gene and reaction knock-outs to identify potential anti–HIV-1 targets, which were subsequently validated by human phytohemagglutinin (PHA) blasts infected with HIV-1. Results: Differential analysis identified several altered biochemical reactions, including increased lysine uptake and oxidative phosphorylation (OXPHOS) activities in the virus optima compared with the host optima. In silico gene and reaction knock-out simulations revealed de novo pyrimidine synthesis, and OXPHOS could serve as potential anti–HIV-1 metabolic targets. In vitro assay confirmed that targeting OXPHOS using metformin could suppress the replication of HIV-1 by 56.6% (385.4 ± 67.5 pg/mL in the metformin-treated group vs. 888.4 ± 32.3 pg/mL in the control group, P < 0.001). Conclusion: Our integrated host-virus genome-scale metabolic study provides insights on potential targets (OXPHOS) for anti-HIV therapies.

8 August 2025 in Viruses
Verified
Journal Article
Open access
PDF file
Runpeng HanRunpeng Han
Runpeng Han
HYHaisheng Yu
Haisheng Yu
GLGUANGMING Li
GUANGMING Li
Lishan SuLishan Su
Lishan Su
LCLiang Cheng
Liang Cheng
Persistent type I interferon (IFN-I) signaling compromises adaptive anti-HIV-1 T cell immunity and promotes viral reservoir persistence, yet its effects on innate lymphoid cells during chronic infection remain unclear. Through integrated single-cell RNA sequencing and functional validation in HIV-1-infected humanized mice with combination antiretroviral therapy (cART) and IFN-I signaling blockade, we reveal IFN-I-induced dysfunction of natural killer (NK) cells and group 3 innate lymphoid cells (ILC3s). Mechanistically, the IFN-I-CD9 axis drives NK cells toward a decidual NK cell-like phenotype, impairing their cytotoxic activity. Furthermore, IFNAR blockade rescues ILC3 functionality, which is critical for IL-17/IL-22-mediated antimicrobial defense and mucosal barrier maintenance. Our study delineates IFN-I-driven immunosuppression across innate lymphocyte compartments and proposes the targeted modulation of this pathway to enhance antiviral and mucosal immunity in HIV-1 management.